Applications of Fluorine in Medicinal Chemistry

Journal of Medicinal Chemistry

Volumn 58, Issue 21, 2015, Pages 8315-8359

  Gillis, Eric P ^a   Eastman, Kyle J ^a   Hill, Matthew D ^a   Donnelly, David J ^a   Meanwell, Nicholas A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; FLUORINE; ISOTOPE;

AQUEOUS SOLUTION; ARTICLE; CHEMICAL INTERACTION; CHEMICAL STRUCTURE; CONFORMATION; DRUG DESIGN; ELECTRON; MEDICINAL CHEMISTRY; MEMBRANE PERMEABILITY; METABOLISM; POSITRON; POSITRON EMISSION TOMOGRAPHY; SOLID STATE; THERMOSTABILITY; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; HALOGENATION; HUMAN; PROCEDURES;

ANIMALS; DRUG DISCOVERY; FLUORINE; FLUORINE RADIOISOTOPES; HALOGENATION; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; POSITRON-EMISSION TOMOGRAPHY;

EID: 84942638403     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00258     Document Type: Article

References (374)

1. Böhm, H. J.; Banner, D.; Bendels, S.; Kansy, M.; Kuhn, B.; Müller, K.; Obst-Sander, U.; Stahl, M. Fluorine in medicinal chemistry ChemBioChem 2004, 5, 637-643
2. Müller, K.; Faeh, C.; Diederich, F. Fluorine in pharmaceuticals: looking beyond intuition Science 2007, 317, 1881-1886
3. Shah, P.; Westwell, A. D. The role of fluorine in medicinal chemistry J. Enzyme Inhib. Med. Chem. 2007, 22, 527-540
4. Bégué, J. P.; Bonnet-Delpon, D. Bioorganic and Medicinal Chemistry of Fluorine; Wiley: Hoboken, NJ, 2007; pp 1-365.
5. Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. Fluorine in medicinal chemistry Chem. Soc. Rev. 2008, 37, 320-330
6. Hagmann, W. K. The many roles for fluorine in medicinal chemistry J. Med. Chem. 2008, 51, 4359-4369
7. Yamazaki, T.; Taguchi, T.; Ojima, I. Unique properties of fluorine and their relevance to medicinal chemistry and chemical biology. In Fluorine in Medicinal Chemistry and Chemical Biology; Ojima, I., Ed.; Wiley-Blackwell, Chichester, U.K., 2009; pp 1-46.
8. Wang, J.; Sánchez-Roselló, M.; Aceña, J. L.; del Pozo, C.; Sorochinsky, A. E.; Fustero, S.; Soloshonok, V. A.; Liu, H. Fluorine in pharmaceutical industry: fluorine-containing drugs introduced to the market in the last decade (2001-2011) Chem. Rev. 2014, 114, 2432-2506
9. Eastman, K. J.; Gillis, E. P.; Meanwell, N. A. Tactical applications of fluorine in drug design and development. Fluorine in Heterocyclic Chemistry, Volume 1, 5-Membered Heterocycles and Macrocycles; Nenajdenko, V., Ed.; Springer International: Cham, Switzerland, 2014; pp 1-54.
10. Nenajdenko, V. G.; Muzalevskiy, V. M.; Shastin, A. V. Polyfluorinated ethanes as versatile fluorinated C2-building blocks for organic synthesis Chem. Rev. 2015, 115, 973-1050
11. Alonso, C.; Martínez de Marigorta, E.; Rubiales, G.; Palacios, F. Carbon trifluoromethylation reactions of hydrocarbon derivatives and heteroarenes Chem. Rev. 2015, 115, 1847-1935
12. Ahrens, T.; Kohlmann, J.; Ahrens, M.; Braun, T. Functionalization of fluorinated molecules by transition-metal-mediated C-F bond activation to access fluorinated building blocks Chem. Rev. 2015, 115, 931-972
13. Yang, X.; Wu, T.; Phipps, R. J.; Toste, F. D. Advances in catalytic enantioselective fluorination, mono-, di-, and trifluoromethylation, and trifluoromethylthiolation reactions Chem. Rev. 2015, 115, 826-870
14. Liang, T.; Neumann, C. N.; Ritter, T. Introduction of fluorine and fluorine-containing functional groups Angew. Chem., Int. Ed. 2013, 52, 8214-8264
15. Champagne, P. A.; Desroches, J.; Hamel, J.-D.; Vandamme, M.; Paquin, J.-F. Monofluorination of organic compounds: 10 years of innovation Chem. Rev. 2015, 115 10.1021/cr500706a
16. Le Bars, D. Fluorine-18 and medical imaging: radiopharmaceuticals for positron emission tomography J. Fluorine Chem. 2006, 127, 1488-1493
17. 13N radiolabels for positron emission tomography Angew. Chem., Int. Ed. 2008, 47, 8998-9033
18. 18F-based radiotracers Am. J. Nucl. Med. Mol. Imaging 2012, 2, 55-76
19. Ametamey, S. M.; Honer, M.; Schubiger, P. A. Molecular imaging with PET Chem. Rev. 2008, 108, 1501-1516
20. Piel, M.; Vernaleken, I.; Rösch, F. Positron emission tomography in CNS drug discovery and drug monitoring J. Med. Chem. 2014, 57, 9232-9258
21. Honer, M.; Gobbi, L.; Martarello, L.; Comley, R. A. Radioligand development for molecular imaging of the central nervous system with positron emission tomography Drug Discovery Today 2014, 19, 1936-1944
22. Zhang, L.; Villalobos, A. Recent advances in the development of PET and SPECT tracers for brain imaging Annu. Rep. Med. Chem. 2012, 47, 105-119
23. Li, Z.; Conti, P. S. Radiopharmaceutical chemistry for positron emission tomography Adv. Drug Delivery Rev. 2010, 62, 1031-1051
24. O'Hagan, D. Understanding organofluorine chemistry. An introduction to the C-F bond Chem. Soc. Rev. 2008, 37, 308-319
25. Hunter, L. The C-F bond as a conformational tool in organic and biological chemistry Beilstein J. Org. Chem. 2010, 6, 38
26. Zimmer, L. E.; Sparr, C.; Gilmour, R. Fluorine conformational effects in organocatalysis: an emerging strategy for molecular design Angew. Chem., Int. Ed. 2011, 50, 11860-11871
27. Buissonneaud, D. Y.; van Mourik, T.; O'Hagan, D. A DFT study on the origin of the fluorine gauche effect in substituted fluoroethanes Tetrahedron 2010, 66, 2196-2202
28. Abraham, R. J.; Chambers, E. J.; Thomas, W. A. Conformational analysis. Part 22. An NMR and theoretical investigation of the gauche effect in fluoroethanols J. Chem. Soc., Perkin Trans. 2 1994, 949-955
29. Abraham, R. J.; Smith, T. A. D.; Thomas, W. A. Conformational analysis. Part 28. OH⋯F hydrogen bonding and the conformation of trans-2-fluorocyclohexanol J. Chem. Soc., Perkin Trans. 2 1996, 9, 1949-1955
30. Dixon, D. A.; Smart, B. E. Conformational energies of 2-fluoroethanol and 2-fluoroacetaldehyde enol: strength of the internal hydrogen bond J. Phys. Chem. 1991, 95, 1609-1612
31. Briggs, C. R. S.; Allen, M. J.; O'Hagan, D.; Tozer, D. J.; Slawin, A. M. Z.; Goeta, A. E.; Howard, J. A. K. The observation of a large gauche preference when 2-fluoroethylamine and 2-fluoroethanol become protonated Org. Biomol. Chem. 2004, 2, 732-740
32. Bakke, J. M.; Bjerkeseth, L. H.; Rønnow, T. E. C. L.; Steinsvoll, K. The conformation of 2-fluoroethanol-Is intramolecular hydrogen bonding important? J. Mol. Struct. 1994, 321, 205-214
33. O'Hagan, D. Organofluorine chemistry: synthesis and conformation of vicinal fluoromethylene motifs J. Org. Chem. 2012, 77, 3689-3699
34. Tavasli, M.; O'Hagan, D.; Pearson, C.; Petty, M. C. The fluorine gauche effect. Langmuir isotherms report the relative conformational stability of (±)-erythro- and (±)-threo-9,10-difluorostearic acids Chem. Commun. 2002, 1226-1227
35. Wu, D.; Tian, A.; Sun, H. Conformational properties of 1,3-difluoropropane J. Phys. Chem. A 1998, 102, 9901-9905
36. Hunter, L.; Kirsch, P.; Slawin, A. M. Z.; O'Hagan, D. Synthesis and structure of stereoisomeric multivicinal hexafluoroalkanes Angew. Chem., Int. Ed. 2009, 48, 5457-5460
37. 2 groups Beilstein J. Org. Chem. 2014, 10, 18-25
38. Hunter, L.; Chung, J. H. Total synthesis of unguisin A J. Org. Chem. 2011, 76, 5502-5505
39. Hunter, L.; Butler, S.; Ludbrook, S. B. Solid phase synthesis of peptides containing backbone-fluorinated amino acids Org. Biomol. Chem. 2012, 10, 8911-8918
40. Hu, X. G.; Thomas, D. S.; Griffith, R.; Hunter, L. Stereoselective fluorination alters the geometry of a cyclic peptide: exploration of backbone-fluorinated analogues of unguisin A Angew. Chem., Int. Ed. 2014, 53, 6176-6179
41. Hunter, L.; Jolliffe, K. A.; Jordan, M. J. T.; Jensen, P.; MacQuart, R. B. Synthesis and conformational analysis of α,β-difluoro-γ-amino acid derivatives Chem.-Eur. J. 2011, 17, 2340-2343
42. Yamamoto, I.; Jordan, M. J. T.; Gavande, N.; Doddareddy, M. R.; Chebib, M.; Hunter, L. The enantiomers of syn-2,3-difluoro-4-aminobutyric acid elicit opposite responses at the GABA C receptor Chem. Commun. 2012, 48, 829-831
43. Abraham, R. J.; Chambers, E. J.; Thomas, W. A. Conformational analysis. Part 22. An NMR and theoretical investigation of the gauche effect in fluoroethanols J. Chem. Soc., Perkin Trans. 2 1994, 949-955
44. Wiberg, K. B.; Murcko, M. A. Rotational barriers: Part 3. 2-Haloethanols J. Mol. Struct.: THEOCHEM 1988, 163, 1-17
45. Hagen, K.; Hedberg, K. Conformational analysis. III. Molecular structure and composition of 2-fluoroethanol as determined by electron diffraction J. Am. Chem. Soc. 1973, 95, 8263-8266
46. Huang, J.; Hedberg, K. Conformational analysis. 13. 2-Fluoroethanol. An investigation of the molecular structure and conformational composition at 20, 156, and 240°C. Estimate of the anti-gauche energy difference J. Am. Chem. Soc. 1989, 111, 6909-6913
47. Buckton, K. S.; Azrak, R. G. Microwave spectrum and intramolecular hydrogen bonding in 2-fluoroethanol J. Chem. Phys. 1970, 52, 5652-5655
48. Jenkins, C. L.; Raines, R. T. Insights on the conformational stability of collagen Nat. Prod. Rep. 2002, 19, 49-59
49. Shoulders, M. D.; Kamer, K. J.; Raines, R. T. Origin of the stability conferred upon collagen by fluorination Bioorg. Med. Chem. Lett. 2009, 19, 3859-3862
50. Dunitz, J. D.; Taylor, R. Organic fluorine hardly ever accepts hydrogen bonds Chem.-Eur. J. 1997, 3, 89-98
51. Dunitz, J. D. Organic fluorine: odd man out ChemBioChem 2004, 5, 614-621
52. Dalvit, C.; Vulpetti, A. Intermolecular and intramolecular hydrogen bonds involving fluorine atoms: implications for recognition, selectivity, and chemical properties ChemMedChem 2012, 7, 262-272
53. Schneider, H.-J. Hydrogen bonds with fluorine. Studies in solution, in gas phase and by computations, conflicting conclusions from crystallographic analyses Chem. Sci. 2012, 3, 1381-1394
54. Champagne, P. A.; Desroches, J.; Paquin, J.-F. Organic fluorine as a hydrogen-bond acceptor: recent examples and applications Synthesis 2015, 47, 306-322
55. Dalvit, C.; Invernizzi, C.; Vulpetti, A. Fluorine as a hydrogen-bond acceptor: experimental evidence and computational calculations Chem.-Eur. J. 2014, 20, 11058-11068
56. Souza, F. R.; Freitas, M. P. Conformational analysis and intramolecular interactions in 2-haloethanols and their methyl ethers Comput. Theor. Chem. 2011, 964, 155-159
57. Andrade, L. A. F.; Silla, J. M.; Duarte, C. J.; Rittnerb, R.; Freitas, M. P. The preferred all-gauche conformations in 3-fluoro-1,2-propanediol Org. Biomol. Chem. 2013, 11, 6766-6771
58. Graton, J.; Wang, Z.; Brossard, A.-M.; Gonçalves Monteiro, D.; Le Questel, J.-Y.; Linclau, B. An unexpected and significantly lower hydrogen-bond-donating capacity of fluorohydrins compared to nonfluorinated alcohols Angew. Chem., Int. Ed. 2012, 51, 6176-6180
59. Myers, A. G.; Barbay, J. K.; Zhong, B. Asymmetric synthesis of chiral organofluorine compounds: use of nonracemic fluoroiodoacetic acid as a practical electrophile and its application to the synthesis of monofluoro hydroxyethylene dipeptide isosteres within a novel series of HIV protease inhibitors J. Am. Chem. Soc. 2001, 123, 7207-7219
60. Hehre, W. J.; Radom, L.; Pople, J. A. Molecular orbital theory of the electronic structure of organic compounds. XII. Conformations, stabilities, and charge distributions in monosubstituted benzenes J. Am. Chem. Soc. 1972, 94, 1496-1504
61. Hummel, W.; Huml, K.; Bürgi, H.-B. Conformational flexibility of the methoxyphenyl group studied by statistical analysis of crystal structure data Helv. Chim. Acta 1988, 71, 1291-1302
62. Brameld, K. A.; Kuhn, B.; Reuter, D. C.; Stahl, M. Small molecule conformational preferences derived from crystal structure data. A medicinal chemistry focused analysis J. Chem. Inf. Model. 2008, 48, 1-24
63. Johnson, F. Allylic strain in six-membered rings Chem. Rev. 1968, 68, 375-413
64. Anderson, G. M.; Kollman, P. A.; Domelsmith, L. N.; Houk, K. N. Methoxy group nonplanarity in o-dimethoxybenzenes. Simple predictive models for conformations and rotational barriers in alkoxyaromatics J. Am. Chem. Soc. 1979, 101, 2344-2352
65. Leroux, F.; Jeschke, P.; Schlosser, M. α-Fluorinated ethers, thioethers, and amines: anomerically biased species Chem. Rev. 2005, 105, 827-856
66. Leroux, F. R.; Manteau, B.; Vors, J. P.; Pazenok, S. Trifluoromethyl ethers-synthesis and properties of an unusual substituent Beilstein J. Org. Chem. 2008, 4, 13 10.3762/bjoc.4.13
67. Manteau, B.; Pazenok, S.; Vors, J. P.; Leroux, F. R. New trends in the chemistry of α-fluorinated ethers, thioethers, amines and phosphines J. Fluorine Chem. 2010, 131, 140-158
68. Horne, D. B.; Bartberger, M. D.; Kaller, M. R.; Monenschein, H.; Zhong, W.; Hitchcock, S. A. Synthesis and conformational analysis of α,α-difluoroalkyl heteroaryl ethers Tetrahedron Lett. 2009, 50, 5452-5455
69. Xing, L.; Blakemore, D. C.; Narayanan, A.; Unwalla, R.; Lovering, F.; Denny, R. A.; Zhou, H.; Bunnage, M. E. Fluorine in drug design: a case study with fluoroanisoles ChemMedChem 2015, 10, 715-726
70. Klocker, J.; Karpfen, A.; Wolschann, P. On the structure and torsional potential of trifluoromethoxybenzene: an ab initio and density functional study Chem. Phys. Lett. 2003, 367, 566-575
71. Massa, M. A.; Spangler, D. P.; Durley, R. C.; Hickory, B. S.; Connolly, D. T.; Witherbee, B. J.; Smith, M. E.; Sikorski, J. A. Novel heteroaryl replacements of aromatic 3-tetrafluoroethoxy substituents in trifluoro-3-(tertiaryamino)-2-propanols as potent inhibitors of cholesteryl ester transfer protein Bioorg. Med. Chem. Lett. 2001, 11, 1625-1628
72. Reinhard, E. J.; Wang, J. L.; Durley, R. C.; Fobian, Y. M.; Grapperhaus, M. L.; Hickory, B. S.; Massa, M. A.; Norton, M. B.; Promo, M. A.; Tollefson, M. B.; Vernier, W. F.; Connolly, D. T.; Witherbee, B. J.; Melton, M. A.; Regina, K. J.; Smith, M. E.; Sikorski, J. A. Discovery of a simple picomolar inhibitor of cholesteryl ester transfer protein J. Med. Chem. 2003, 46, 2152-2168
73. Lankin, D. C.; Chandrakumar, N. S.; Rao, S. N.; Spangler, D. P.; Snyder, J. P. Protonated 3-fluoropiperidines: an unusual fluoro directing effect and a test for quantitative theories of solvation J. Am. Chem. Soc. 1993, 115, 3356-3357
74. Snyder, J. P.; Chandrakumar, N. S.; Sato, H.; Lankin, D. C. The unexpected diaxial orientation of cis-3,5-difluoropiperidine in water: a potent CF⋯NH charge-dipole effect J. Am. Chem. Soc. 2000, 122, 544-545
75. Sun, A.; Lankin, D. C.; Hardcastle, K.; Snyder, J. P. 3-Fluoropiperidines and N-methyl-3-fluoropiperidinium salts: the persistence of axial fluorine Chem.-Eur. J. 2005, 11, 1579-1591
76. Deniau, G.; Slawin, A. M. Z.; Lebl, T.; Chorki, F.; Issberner, J. P.; van Mourik, T.; Heygate, J. M.; Lambert, J. J.; Etherington, L. A.; Sillar, K. T.; O'Hagan, D. Synthesis, conformation and biological evaluation of the enantiomers of 3-fluoro-γ-aminobutyric acid ((R)- and (S)-3F-GABA): an analogue of the neurotransmittter GABA ChemBioChem 2007, 8, 2265-2274
77. Clift, M. D.; Ji, H.; Deniau, G. P.; O'Hagan, D.; Silverman, R. B. Enantiomers of 4-amino-3-fluorobutanoic acid as substrates for γ-aminobutyric acid aminotransferase. Conformational probes for GABA binding Biochemistry 2007, 46, 13819-13828
78. C receptors Chem. Commun. 2011, 47, 7956-7958
79. Crittenden, D. L.; Chebib, M.; Jordan, M. J. T. A quantitative structure-activity relationship investigation into agonist binding at GABAC receptors J. Mol. Struct.: THEOCHEM 2005, 755, 81-89
80. Chia, P. W.; Livesey, M. R.; Slawin, A. M. Z.; Van Mourik, T.; Wyllie, D. J. A.; O'Hagan, D. 3-Fluoro-N-methyl- d -aspartic acid (3F-NMDA) stereoisomers as conformational probes for exploring agonist binding at NMDA receptors Chem.-Eur. J. 2012, 18, 8813-8819
81. Winkler, M.; Moraux, T.; Khairy, H. A.; Scott, R. H.; Slawin, A. M. Z.; O'Hagan, D. Synthesis and vanilloid receptor (TRPV1) activity of the enantiomers of α-fluorinated capsaicin ChemBioChem 2009, 10, 823-828
82. Yang, F.; Xiao, X.; Cheng, W.; Yang, W.; Yu, P.; Song, Z.; Yarov-Yarovoy, V.; Zheng, J. Structural mechanism underlying capsaicin binding and activation of the TRPV1 ion channel. Nature Chem. Biol. 2015, in press. DOI: 10.1038/nchembio.1835
83. Peddie, V.; Butcher, R. J.; Robinson, W. T.; Wilce, M. C. J.; Traore, D. A. K.; Abell, A. D. Synthesis and conformation of fluorinated β-peptidic compounds Chem.-Eur. J. 2012, 18, 6655-6662
84. O'Hagan, D.; Bilton, C.; Howard, J. A. K.; Knight, L.; Tozer, D. J. The preferred conformation of N-β-fluoroethylamides. Observation of the fluorine amide gauche effect J. Chem. Soc., Perkin Trans. 2 2000, 605-607
85. O'Hagan, D.; Rzepa, H. S. Some influences of fluorine in bioorganic chemistry Chem. Commun. 1997, 645-652
86. Bell, I. M.; Bednar, R. A.; Fay, J. F.; Gallicchio, S. N.; Hochman, J. H.; McMasters, D. R.; Miller-Stein, C.; Moore, E. L.; Mosser, S. D.; Pudvah, N. T.; Quigley, A. G.; Salvatore, C. A.; Stump, C. A.; Theberge, C. R.; Wong, B. K.; Zartman, C. B.; Zhang, X. F.; Kane, S. A.; Graham, S. L.; Vacca, J. P.; Williams, T. M. Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists Bioorg. Med. Chem. Lett. 2006, 16, 6165-6169
87. Bonomo, S.; Tosco, P.; Giorgis, M.; Lolli, M.; Fruttero, R. The role of fluorine in stabilizing the bioactive conformation of dihydroorotate dehydrogenase inhibitors J. Mol. Model. 2013, 19, 1099-1107
88. Stump, C. A.; Bell, I. M.; Bednar, R. A.; Fay, J. F.; Gallicchio, S. N.; Hershey, J. C.; Jelley, R.; Kreatsoulas, C.; Moore, E. L.; Mosser, S. D.; Quigley, A. G.; Roller, S. A.; Salvatore, C. A.; Sharik, S. S.; Theberge, C. R.; Zartman, C. B.; Kane, S. A.; Graham, S. L.; Selnick, H. G.; Vacca, J. P.; Williams, T. M. Identification of potent, highly constrained CGRP receptor antagonists Bioorg. Med. Chem. Lett. 2010, 20, 2572-2576
89. n polypeptides J. Am. Chem. Soc. 2002, 124, 7857-7865
90. Hinderaker, M. P.; Raines, R. T. An electronic effect on protein structure Protein Sci. 2003, 12, 1188-1194
91. Park, S.; Radmer, R. J.; Klein, T. E.; Pande, V. S. A new set of molecular mechanics parameters for hydroxyproline and its use in molecular dynamics simulations of collagen-like peptides J. Comput. Chem. 2005, 26, 1612-1616
92. DeRider, M. L.; Wilkens, S. J.; Waddell, M. J.; Bretscher, L. E.; Weinhold, F.; Raines, R. T.; Markley, J. L. Collagen stability: insights from NMR spectroscopic and hybrid density functional computational investigations of the effect of electronegative substituents on prolyl ring conformations J. Am. Chem. Soc. 2002, 124, 2497-2505
93. Hodges, J. A.; Raines, R. T. Stereoelectronic and steric effects in the collagen triple helix: toward a code for strand association J. Am. Chem. Soc. 2005, 127, 15923-15932
94. Holmgren, S. K.; Taylor, K. M.; Bretscher, L. E.; Raines, R. T. Code for collagen's stability deciphered Nature 1998, 392, 666-667
95. Bretscher, L. E.; Jenkins, C. L.; Taylor, K. M.; DeRider, M. L.; Raines, R. T. Conformational stability of collagen relies on a stereoelectronic effect J. Am. Chem. Soc. 2001, 123, 777-778
96. Hodges, J. A.; Raines, R. T. Stereoelectronic effects on collagen stability: the dichotomy of 4-fluoroproline diastereomers J. Am. Chem. Soc. 2003, 125, 9262-9263
97. 10 does not J. Am. Chem. Soc. 2003, 125, 9922-9923
98. Doi, M.; Nishi, Y.; Kiritoshi, N.; Iwata, T.; Nago, M.; Nakano, H.; Uchiyama, S.; Nakazawa, T.; Wakamiya, T.; Kobayashi, Y. Simple and efficient syntheses of Boc- and Fmoc-protected 4(R)- and 4(S)-fluoroproline solely from 4(R)-hydroxyproline Tetrahedron 2002, 58, 8453-8459
99. Raines, R. T. 2005 Emil Thomas Kaiser award Protein Sci. 2006, 15, 1219-1225
100. Bella, J.; Brodsky, B.; Berman, H. M. Hydration structure of a collagen peptide Structure 1995, 3, 893-906
101. Hodges, J. A.; Raines, R. T. Energetics of an n → π∗ interaction that impacts protein structure Org. Lett. 2006, 8, 4695-4697
102. Choudhary, A.; Newberry, R. W.; Raines, R. T. n →π∗ interactions engender chirality in carbonyl groups Org. Lett. 2014, 16, 3421-3423
103. Kim, W.; Hardcastle, K. I.; Conticello, V. P. Fluoroproline flip-flop: regiochemical reversal of a stereoelectronic effect on peptide and protein structures Angew. Chem., Int. Ed. 2006, 45, 8141-8145
104. Kitamoto, T.; Ozawa, T.; Abe, M.; Marubayashi, S.; Yamazaki, T. Incorporation of fluoroprolines to proctolin: study on the effect of a fluorine atom toward peptidic conformation J. Fluorine Chem. 2008, 129, 286-293
105. Fukushima, H.; Hiratate, A.; Takahashi, M.; Saito, M.; Munetomo, E.; Kitano, K.; Saito, H.; Takaoka, Y.; Yamamoto, K. Synthesis and structure-activity relationships of potent 3- or 4-substituted-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors Bioorg. Med. Chem. 2004, 12, 6053-6061
106. Jansen, K.; Heirbaut, L.; Verkerk, R.; Cheng, J. D.; Joossens, J.; Cos, P.; Maes, L.; Lambeir, A. M.; De Meester, I.; Augustyns, K.; Van Der Veken, P. Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP) J. Med. Chem. 2014, 57, 3053-3074
107. Liu, P.; Sharon, A.; Chu, C. K. Fluorinated nucleosides: synthesis and biological implication J. Fluorine Chem. 2008, 129, 743-766
108. Qiu, X.-L.; Xu, X.-H.; Qing, F.-L. Recent advances in the synthesis of fluorinated nucleosides Tetrahedron 2010, 66, 789-843
109. Thibaudeau, C.; Acharya, P.; Chattopadhyaya, J. Stereoelectronic Effects in Nucelosides and Nucleotides and Their Structural Implications, 2 nd ed.; Uppsala University Press: Uppsala, Sweden, 2005.
110. Barchi, J. J., Jr; Jeong, L. S.; Siddiqui, M. A.; Marquez, V. E. Conformational analysis of the complete series of 2′ and 3′ monofluorinated dideoxyuridines J. Biochem. Biophys. Methods 1997, 34, 11-29
111. Seela, F.; Chittepu, P. 6-Azauracil or 8-aza-7-deazaadenine nucleosides and oligonucleotides: the effect of 2′-fluoro substituents and nucleobase nitrogens on conformation and base pairing Org. Biomol. Chem. 2008, 6, 596-607
112. Barchi, J. J., Jr.; Karki, R. G.; Nicklaus, M. C.; Siddiqui, M. A.; George, C.; Mikhailopulo, I. A.; Marquez, V. E. Comprehensive structural studies of 2′,3′-difluorinated nucleosides: comparison of theory, solution, and solid state J. Am. Chem. Soc. 2008, 130, 9048-9057
113. Watts, J. K.; Damha, M. J. 2′F-Arabinonucleic acids (2′F-ANA)-history, properties, and new frontiers Can. J. Chem. 2008, 86, 641-656
114. Blandin, M.; Son, T. D.; Catlin, J. C.; Guschlbauer, W. Nucleoside conformations. 16. Nuclear magnetic resonance and circular dichroism studies on pyrimidine-2′-fluoro-2′-deoxyribonucleosides Biochim. Biophys. Acta 1974, 361, 249-256
115. Sivets, G. G.; Kalinichenko, E. N.; Mikhailopulo, I. A. Synthesis and conformational analysis of 1′- and 3′-substituted 2-deoxy-2-fluoro- d -ribofuranosyl nucleosides Helv. Chim. Acta 2007, 90, 1818-1836
116. Marquez, V. E.; Tseng, C. K. H.; Mitsuya, H.; Aoki, S.; Kelley, J. A.; Ford, H., Jr.; Roth, J. S.; Broder, S.; Johns, D. G.; Driscoll, J. S. Acid-stable 2′-fluoro purine dideoxynucleosides as active agents against HIV J. Med. Chem. 1990, 33, 978-985
117. Van Roey, P.; Salerno, J. M.; Chu, C. K.; Schinazi, R. F. Correlation between preferred sugar ring conformation and activity of nucleoside analogues against human immunodeficiency virus Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 3929-3933
118. Marquez, V. E.; Tseng, C. K. H.; Kelley, J. A.; Mitsuya, H.; Broder, S.; Roth, J. S.; Driscoll, J. S. 2′,3′-Dideoxy-2′-fluoro-ara-A. An acid-stable purine nucleoside active against human immunodeficiency virus (HIV) Biochem. Pharmacol. 1987, 36, 2719-2722
119. Graul, A.; Silvestre, J.; Castaner, J. Lodenosine. Anti-HIV, reverse transcriptase inhibitor Drugs Future 1998, 23, 1176-1189
120. Sivets, G. G.; Kalinichenko, E. N.; Mikhailopulo, I. A.; Detorio, M. A.; McBrayer, T. R.; Whitaker, T.; Schinazi, R. F. Synthesis and antiviral activity of purine 2′,3′-dideoxy-2′,3′-difluoro- d -arabinofuranosyl nucleosides Nucleosides, Nucleotides Nucleic Acids 2009, 28, 519-536
121. Martínez-Montero, S.; Deleavey, G. F.; Kulkarni, A.; Martín-Pintado, N.; Lindovska, P.; Thomson, M.; González, C.; Götte, M.; Damha, M. J. Rigid 2′,4′-difluororibonucleosides: synthesis, conformational analysis, and incorporation into nascent RNA by HCV polymerase J. Org. Chem. 2014, 79, 5627-5635
122. Gore, K. R.; Harikrishna, S.; Pradeepkumar, P. I. Influence of 2′-fluoro versus 2′-O-methyl substituent on the sugar puckering of 4′-C-aminomethyluridine J. Org. Chem. 2013, 78, 9956-9962
123. Anzahaee, M. Y.; Watts, J. K.; Alla, N. R.; Nicholson, A. W.; Damha, M. J. Energetically important C-H⋯F-C pseudohydrogen bonding in water: evidence and application to rational design of oligonucleotides with high binding affinity J. Am. Chem. Soc. 2011, 133, 728-731
124. Mikhailopulo, I. A.; Pricota, T. I.; Sivets, G. G.; Altona, C. 2′-Chloro-2′,3′-dideoxy-3′-fluoro- d -ribonucleosides: synthesis, stereospecificity, some chemical transformations, and conformational analysis J. Org. Chem. 2003, 68, 5897-5908
125. Hui, C. K.; Lau, G. K. K. Clevudine for the treatment of chronic hepatitis B virus infection Expert Opin. Invest. Drugs 2005, 14, 1277-1284
126. Chong, Y.; Chu, C. K. Understanding the unique mechanism of L-FMAU (clevudine) against hepatitis B virus: molecular dynamics studies Bioorg. Med. Chem. Lett. 2002, 12, 3459-3462
127. Alabugin, I. V.; Zeidan, T. A. Stereoelectronic effects and general trends in hyperconjugative acceptor ability of σ bonds J. Am. Chem. Soc. 2002, 124, 3175-3185
128. Meanwell, N. A. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety Chem. Res. Toxicol. 2011, 24, 1420-1456
129. Hopkins, A. L.; Keserü, G. M.; Leeson, P. D.; Rees, D. C.; Reynolds, C. H. The role of ligand efficiency metrics in drug discovery Nat. Rev. Drug Discovery 2014, 13, 105-121
130. Ritchie, T. J.; Macdonald, S. J. F. How drug-like are "ugly" drugs: do drug-likeness metrics predict ADME behaviour in humans? Drug Discovery Today 2014, 19, 489-495
131. Wager, T. T.; Kormos, B. L.; Brady, J. T.; Will, Y.; Aleo, M. D.; Stedman, D. B.; Kuhn, M.; Chandrasekaran, R. Y. Improving the odds of success in drug discovery: choosing the best compounds for in vivo toxicology studies J. Med. Chem. 2013, 56, 9771-9779
132. Tarcsay, A.; Keserú, G. M. Contributions of molecular properties to drug promiscuity J. Med. Chem. 2013, 56, 1789-1795
133. Yusof, I.; Segall, M. D. Considering the impact drug-like properties have on the chance of success Drug Discovery Today 2013, 18, 659-666
134. Morgenthaler, M.; Schweizer, E.; Hoffmann-Röder, A.; Benini, F.; Martin, R. E.; Jaeschke, G.; Wagner, B.; Fischer, H.; Bendels, S.; Zimmerli, D.; Schneider, J.; Diederich, F.; Kansy, M.; Müller, K. Predicting and tuning physicochemical properties in lead optimization: amine basicities ChemMedChem 2007, 2, 1100-1115
135. Sani, M.; Volonterio, A.; Zanda, M. The trifluoroethylamine function as peptide bond replacement ChemMedChem 2007, 2, 1693-1700
136. Jagodzinska, M.; Huguenot, F.; Candiani, G.; Zanda, M. Assessing the bioisosterism of the trifluoromethyl group with a protease probe ChemMedChem 2009, 4, 49-51
137. Gauthier, J. Y.; Chauret, N.; Cromlish, W.; Desmarais, S.; Duong, L. T.; Falgueyret, J. P.; Kimmel, D. B.; Lamontagne, S.; Léger, S.; LeRiche, T.; Li, C. S.; Massé, F.; McKay, D. J.; Nicoll-Griffith, D. A.; Oballa, R. M.; Palmer, J. T.; Percival, M. D.; Riendeau, D.; Robichaud, J.; Rodan, G. A.; Rodan, S. B.; Seto, C.; Thérien, M.; Truong, V. L.; Venuti, M. C.; Wesolowski, G.; Young, R. N.; Zamboni, R.; Black, W. C. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K Bioorg. Med. Chem. Lett. 2008, 18, 923-928
138. Van Niel, M. B.; Collins, I.; Beer, M. S.; Broughton, H. B.; Cheng, S. K. F.; Goodacre, S. C.; Heald, A.; Locker, K. L.; MacLeod, A. M.; Morrison, D.; Moyes, C. R.; O'Connor, D.; Pike, A.; Rowley, M.; Russell, M. G. N.; Sohal, B.; Stanton, J. A.; Thomas, S.; Verrier, H.; Watt, A. P.; Castro, J. L. Fluorination of 3-(3-(piperidin-1-yl)propyl)indoles and 3-(3-(piperazin-1-yl)propyl)indoles gives selective human 5-HT(1D) receptor ligands with improved pharmacokinetic profiles J. Med. Chem. 1999, 42, 2087-2104
139. Cox, C. D.; Coleman, P. J.; Breslin, M. J.; Whitman, D. B.; Garbaccio, R. M.; Fraley, M. E.; Buser, C. A.; Walsh, E. S.; Hamilton, K.; Schaber, M. D.; Lobell, R. B.; Tao, W.; Davide, J. P.; Diehl, R. E.; Abrams, M. T.; South, V. J.; Huber, H. E.; Torrent, M.; Prueksaritanont, T.; Li, C.; Slaughter, D. E.; Mahan, E.; Fernandez-Metzler, C.; Yan, Y.; Kuo, L. C.; Kohl, N. E.; Hartman, G. D. Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancer J. Med. Chem. 2008, 51, 4239-4252
140. Cerny, M. A.; Hanzlik, R. P. Cyclopropylamine inactivation of cytochromes P450: role of metabolic intermediate complexes Arch. Biochem. Biophys. 2005, 436, 265-275
141. Goncharov, N. V.; Jenkins, R. O.; Radilov, A. S. Toxicology of fluoroacetate: a review, with possible directions for therapy research J. Appl. Toxicol. 2006, 26, 148-161
142. Cox, C. D.; Breslin, M. J.; Whitman, D. B.; Coleman, P. J.; Garbaccio, R. M.; Fraley, M. E.; Zrada, M. M.; Buser, C. A.; Walsh, E. S.; Hamilton, K.; Lobell, R. B.; Tao, W.; Abrams, M. T.; South, V. J.; Huber, H. E.; Kohl, N. E.; Hartman, G. D. Kinesin spindle protein (KSP) inhibitors. Part V: discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by β-fluorination to overcome cellular efflux by P-glycoprotein Bioorg. Med. Chem. Lett. 2007, 17, 2697-2702
143. Hicken, E. J.; Marmsater, F. P.; Munson, M. C.; Schlachter, S. T.; Robinson, J. E.; Allen, S.; Burgess, L. E.; Delisle, R. K.; Rizzi, J. P.; Topalov, G. T.; Zhao, Q.; Hicks, J. M.; Kallan, N. C.; Tarlton, E.; Allen, A.; Callejo, M.; Cox, A.; Rana, S.; Klopfenstein, N.; Woessner, R.; Lyssikatos, J. P. Discovery of a novel class of imidazo[1,2-a]pyridines with potent PDGFR activity and oral bioavailability ACS Med. Chem. Lett. 2014, 5, 78-83
144. McDonald, I. M.; Mate, R. A.; Zusi, F. C.; Huang, H.; Post-Munson, D. J.; Ferrante, M. A.; Gallagher, L.; Bertekap, R. L., Jr; Knox, R. J.; Robertson, B. J.; Harden, D. G.; Morgan, D. G.; Lodge, N. J.; Dworetzky, S. I.; Olson, R. E.; Macor, J. E. Discovery of a novel series of quinolone α7 nicotinic acetylcholine receptor agonists Bioorg. Med. Chem. Lett. 2013, 23, 1684-1688
145. Reck, F.; Alm, R.; Brassil, P.; Newman, J.; Dejonge, B.; Eyermann, C. J.; Breault, G.; Breen, J.; Comita-Prevoir, J.; Cronin, M.; Davis, H.; Ehmann, D.; Galullo, V.; Geng, B.; Grebe, T.; Morningstar, M.; Walker, P.; Hayter, B.; Fisher, S. Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II: broad-spectrum antibacterial agents with reduced hERG activity J. Med. Chem. 2011, 54, 7834-7847
146. a: antibacterial agents with an improved safety profile J. Med. Chem. 2012, 55, 6916-6933
147. Hameed, P. S.; Patil, V.; Solapure, S.; Sharma, U.; Madhavapeddi, P.; Raichurkar, A.; Chinnapattu, M.; Manjrekar, P.; Shanbhag, G.; Puttur, J.; Shinde, V.; Menasinakai, S.; Rudrapatana, S.; Achar, V.; Awasthy, D.; Nandishaiah, R.; Humnabadkar, V.; Ghosh, A.; Narayan, C.; Ramya, V. K.; Kaur, P.; Sharma, S.; Werngren, J.; Hoffner, S.; Panduga, V.; Kumar, C. N. N.; Reddy, J.; Kumar, K. N. M.; Ganguly, S.; Bharath, S.; Bheemarao, U.; Mukherjee, K.; Arora, U.; Gaonkar, S.; Coulson, M.; Waterson, D.; Sambandamurthy, V. K.; De Sousa, S. M. Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against mycobacterium tuberculosis J. Med. Chem. 2014, 57, 4889-4905
148. Hanessian, S.; Saavedra, O. M.; Vilchis-Reyes, M. A.; Maianti, J. P.; Kanazawa, H.; Dozzo, P.; Matias, R. D.; Serio, A.; Kondo, J. Synthesis, broad spectrum antibacterial activity, and X-ray co-crystal structure of the decoding bacterial ribosomal A-site with 4′-deoxy-4′-fluoro neomycin analogs Chem. Sci. 2014, 5, 4621-4632
149. Maianti, J. P.; Kanazawa, H.; Dozzo, P.; Matias, R. D.; Feeney, L. A.; Armstrong, E. S.; Hildebrandt, D. J.; Kane, T. R.; Gliedt, M. J.; Goldblum, A. A.; Linsell, M. S.; Aggen, J. B.; Kondo, J.; Hanessian, S. Toxicity modulation, resistance enzyme evasion, and A-site X-ray structure of broad-spectrum antibacterial neomycin analogs ACS Chem. Biol. 2014, 9, 2067-2073
150. Hansch, C.; Leo, A.; Unger, S. H.; Kim, K. H.; Nikaitani, D.; Lien, E. J. Aromatic substituent constants for structure-activity correlations J. Med. Chem. 1973, 16, 1207-1216
151. Hansch, C.; Leo, A.; Taft, R. W. A survey of Hammett substituent constants and resonance and field parameters Chem. Rev. 1991, 91, 165-195
152. Iwasa, J.; Fujita, T.; Hansch, C. Substituent constants for aliphatic functions obtained from partition coefficients J. Med. Chem. 1965, 8, 150-153
153. Rouxel, C.; Le Droumaguet, C.; Macé, Y.; Clift, S.; Mongin, O.; Magnier, E.; Blanchard-Desce, M. Octupolar derivatives functionalized with superacceptor peripheral groups: synthesis and evaluation of the electron-withdrawing ability of potent unusual groups Chem.-Eur. J. 2012, 18, 12487-12497
154. Yagupolskii, L. M. Aromatic compounds with new fluorine-containing substituents J. Fluorine Chem. 1987, 36, 1-28
155. 5) organic molecules J. Fluorine Chem. 2012, 143, 57-93
156. Park, B. K.; Kitteringham, N. R.; O'Neill, P. M. Metabolism of fluorine-containing drugs Annu. Rev. Pharmacool. Toxicol. 2001, 41, 443-470
157. Gleeson, P.; Bravi, G.; Modi, S.; Lowe, D. ADMET rules of thumb II: a comparison of the effects of common substituents on a range of ADMET parameters Bioorg. Med. Chem. 2009, 17, 5906-5919
158. Dossetter, A. G. A statistical analysis of in vitro human microsomal metabolic stability of small phenyl group substituents, leading to improved design sets for parallel SAR exploration of a chemical series Bioorg. Med. Chem. 2010, 18, 4405-4414
159. Qiu, J.; Stevenson, S. H.; O'Beirne, M. J.; Silverman, R. B. 2,6-Difluorophenol as a bioisostere of a carboxylic acid: bioisosteric analogues of γ-aminobutyric acid J. Med. Chem. 1999, 42, 329-332
160. Nicolaou, I.; Zika, C.; Demopoulos, V. J. [1-(3,5-Difluoro-4-hydroxyphenyl)-1H-pyrrol-3-yl]phenylmethanone as a bioisostere of a carboxylic acid aldose reductase inhibitor J. Med. Chem. 2004, 47, 2706-2709
161. Alexiou, P.; Demopoulos, V. J. A diverse series of substituted benzenesulfonamides as aldose reductase inhibitors with antioxidant activity: design, synthesis, and in vitro activity J. Med. Chem. 2010, 53, 7756-7766
162. Kotsampasakou, E.; Demopoulos, V. J. Synthesis of derivatives of the keto-pyrrolyl-difluorophenol scaffold: some structural aspects for aldose reductase inhibitory activity and selectivity Bioorg. Med. Chem. 2013, 21, 869-873
163. Bey, E.; Marchais-Oberwinkler, S.; Kruchten, P.; Frotscher, M.; Werth, R.; Oster, A.; Algül, O.; Neugebauer, A.; Hartmann, R. W. Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases Bioorg. Med. Chem. 2008, 16, 6423-6435
164. Bey, E.; Marchais-Oberwinkler, S.; Negri, M.; Kruchten, P.; Oster, A.; Klein, T.; Spadaro, A.; Werth, R.; Frotscher, M.; Birk, B.; Hartmann, R. W. New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitory activity and selectivity J. Med. Chem. 2009, 52, 6724-6743
165. Bey, E.; Marchais-Oberwinkler, S.; Werth, R.; Negri, M.; Al-Soud, Y. A.; Kruchten, P.; Oster, A.; Frotscher, M.; Birk, B.; Hartmann, R. W. Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) J. Med. Chem. 2008, 51, 6725-6739
166. Kirk, K. L. Selective fluorination in drug design and development: an overview of biochemical rationales Curr. Top. Med. Chem. 2006, 6, 1447-1456
167. Lou, Y.; Sweeney, Z. K.; Kuglstatter, A.; Davis, D.; Goldstein, D. M.; Han, X.; Hong, J.; kocer, B.; Kondru, R. K.; Litman, R.; McIntosh, J.; Sarma, K.; Suh, J.; Taygerly, J.; Owens, T. D. Finding the perfect spot for fluorine: improving potency up to 40-fold during a rational fluorine scan of Bruton's tyrosine kinase (BTK)inhibitor scaffold Bioorg. Med. Chem. Lett. 2015, 25, 367-371
168. Deng, X.; Kokkonda, S.; El Mazouni, F.; White, J.; Burrows, J. N.; Kaminsky, W.; Charman, S. A.; Matthews, D.; Rathod, P. K.; Phillips, M. A. Fluorine modulates species selectivity in the triazolopyrimidine class of Plasmodium falciparum didhydroorotate dehydrogenase inhibitors J. Med. Chem. 2014, 57, 5381-5394
169. Boehringer, M.; Fischer, H.; Hennig, M.; Hunziker, D.; Huwyler, J.; Kuhn, B.; Loeffer, B. M.; Luebbers, T.; Mattei, P.; Narquizian, R.; Sebokova, E.; Sprecher, U.; Wessel, H. P. Aryl- and heteroaryl-substituted aminobenzo[a]quinolizines as dipeptidyl peptidase IV inhibitors Bioorg. Med. Chem. Lett. 2010, 20, 1106-1108
170. Mayer, T. U.; Kapoor, T. M.; Haggarty, S. J.; King, R. W.; Schreiber, S. L.; Mitchison, T. J. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen Science 1999, 286, 971-974
171. Maliga, Z.; Kapoor, T. M.; Mitchison, T. J. Evidence that monastrol is an allosteric inhibitor of the mitotic kinesin Eg5 Chem. Biol. 2002, 9, 989-996
172. Kristal Kaan, H. Y.; Ulaganathan, V.; Rath, O.; Prokopcová, H.; Dallinger, D.; Kappe, C. O.; Kozielski, F. Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol J. Med. Chem. 2010, 53, 5676-5683
173. Prokopcová, H.; Dallinger, D.; Uray, G.; Kaan, H. Y. K.; Ulaganathan, V.; Kozielski, F.; Laggner, C.; Kappe, C. O. Structure-activity relationships and molecular docking of novel dihydropyrimidine-based mitotic Eg5 inhibitors ChemMedChem 2010, 5, 1760-1769
174. Garcia-Saez, I.; DeBonis, S.; Lopez, R.; Trucco, F.; Rousseau, B.; Thuéry, P.; Kozielski, F. Structure of human Eg5 in complex with a new monastrol-based inhibitor bound in the R configuration J. Biol. Chem. 2007, 282, 9740-9747
175. Olsen, J. A.; Banner, D. W.; Seiler, P.; Sander, U. O.; D'Arcy, A.; Stihle, M.; Müller, K.; Diederich, F. A fluorine scan of thrombin inhibitors to map the fluorophilicity/fluorophobicity of an enzyme active site: evidence for C-F⋯C=O interactions Angew. Chem., Int. Ed. 2003, 42, 2507-2511
176. Olsen, J. A.; Banner, D. W.; Seiler, P.; Wagner, B.; Tschopp, T.; Obst-Sander, U.; Kansy, M.; Müller, K.; Diederich, F. Fluorine interactions at the thrombin active site: protein backbone fragments H-Cα-C=O comprise a favorable C-F environment and interactions of C-F with electrophiles ChemBioChem 2004, 5, 666-675
177. Hof, F.; Scofield, D. M.; Schweizer, W. B.; Diederich, F. A weak attractive interaction between organic fluorine and an amide group Angew. Chem., Int. Ed. 2004, 43, 5056-5059
178. Schweizer, E.; Hoffmann-Röder, A.; Olsen, J. A.; Seiler, P.; Obst-Sander, U.; Wagner, B.; Kansy, M.; Banner, D. W.; Diederich, F. Multipolar interactions in the D pocket of thrombin: large differences between tricyclic imide and lactam inhibitors Org. Biomol. Chem. 2006, 4, 2364-2375
179. Van Den Berg, J. A.; Seddon, K. R. Critical evaluation of C-H⋯X hydrogen bonding in the crystalline state Cryst. Growth Des. 2003, 3, 643-661
180. Carosati, E.; Sciabola, S.; Cruciani, G. Hydrogen bonding interactions of covalently bonded fluorine atoms: from crystallographic data to a new angular function in the GRID force field J. Med. Chem. 2004, 47, 5114-5125
181. D'Oria, E.; Novoa, J. J. On the hydrogen bond nature of the C-HF interactions in molecular crystals. An exhaustive investigation combining a crystallographic database search and ab initio theoretical calculations CrystEngComm 2008, 10, 423-436
182. Zhou, P.; Zou, J.; Tian, F.; Shang, Z. Fluorine bonding-How does it work in protein-ligand interactions? J. Chem. Inf. Model. 2009, 49, 2344-2355
183. Ouvrard, C.; Berthelot, M.; Laurence, C. The first basicity scale of fluoro-, chloro-, bromo- and iodo-alkanes: some cross-comparisons with simple alkyl derivatives of other elements J. Chem. Soc., Perkin Trans. 2 1999, 1357-1362
184. Laurence, C.; Berthelot, M. Observations on the strength of hydrogen bonding Perspect. Drug Discovery Des. 2000, 18, 39-60
185. BHX database: toward a better understanding of hydrogen-bond basicity for medicinal chemists J. Med. Chem. 2009, 52, 4073-4086
186. Dunitz, J. D.; Gavezzotti, A. Molecular recognition in organic crystals: directed intermolecular bonds or nonlocalized bonding? Angew. Chem., Int. Ed. 2005, 44, 1766-1787
187. Joseph, J.; Jemmis, E. D. Red-, blue-, or no-shift in hydrogen bonds-a unified explanation J. Am. Chem. Soc. 2007, 129, 4620-4632
188. FH coupling in 2-fluorophenol revisited: is intramolecular hydrogen bond responsible for this long-range coupling? Magn. Reson. Chem. 2011, 49, 763-767
189. F,H(O) coupling constant in 2′-fluoroflavonol Magn. Reson. Chem. 2012, 50, 551-556
190. Struble, M. D.; Strull, J.; Patel, K.; Siegler, M. A.; Lectka, T. Modulating "jousting" C-F⋯H-C interactions with a bit of hydrogen bonding J. Org. Chem. 2014, 79, 1-6
191. Struble, M. D.; Kelly, C.; Siegler, M. A.; Lectka, T. Search for a strong, virtually "no-shift" hydrogen bond: a cage molecule with an exceptional OH⋯F interaction Angew. Chem., Int. Ed. 2014, 53, 8924-8928
192. Parlow, J. J.; Stevens, A. M.; Stegeman, R. A.; Stallings, W. C.; Kurumbail, R. G.; South, M. S. Synthesis and crystal structures of substituted benzenes and benzoquinones as tissue factor VIIa inhibitors J. Med. Chem. 2003, 46, 4297-4312
193. Parlow, J. J.; Kurumbail, R. G.; Stegeman, R. A.; Stevens, A. M.; Stallings, W. C.; South, M. S. Design, synthesis, and crystal structure of selective 2-pyridone tissue factor VIIa inhibitors J. Med. Chem. 2003, 46, 4696-4701
194. Parlow, J. J.; Kurumbail, R. G.; Stegeman, R. A.; Stevens, A. M.; Stallings, W. C.; South, M. S. Synthesis and X-ray crystal structures of substituted fluorobenzene and benzoquinone inhibitors of the tissue factor VIIa complex Bioorg. Med. Chem. Lett. 2003, 13, 3721-3725
195. Maryanoff, B. E.; McComsey, D. F.; Costanzo, M. J.; Yabut, S. C.; Lu, T.; Player, M. R.; Giardino, E. C.; Damiano, B. P. Exploration of potential prodrugs of RWJ-445167, an oxyguanidine-based dual inhibitor of thrombin and factor Xa Chem. Biol. Drug Des. 2006, 68, 29-36
196. Lee, L.; Kreutter, K. D.; Pan, W.; Crysler, C.; Spurlino, J.; Player, M. R.; Tomczuk, B.; Lu, T. 2-(2-Chloro-6-fluorophenyl)acetamides as potent thrombin inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 6266-6269
197. Kreutter, K. D.; Lu, T.; Lee, L.; Giardino, E. C.; Patel, S.; Huang, H.; Xu, G.; Fitzgerald, M.; Haertlein, B. J.; Mohan, V.; Crysler, C.; Eisennagel, S.; Dasgupta, M.; McMillan, M.; Spurlino, J. C.; Huebert, N. D.; Maryanoff, B. E.; Tomczuk, B. E.; Damiano, B. P.; Player, M. R. Orally efficacious thrombin inhibitors with cyanofluorophenylacetamide as the P2 motif Bioorg. Med. Chem. Lett. 2008, 18, 2865-2870
198. Burgey, C. S.; Robinson, K. A.; Lyle, T. A.; Sanderson, P. E. J.; Lewis, S. D.; Lucas, B. J.; Krueger, J. A.; Singh, R.; Miller-Stein, C.; White, R. B.; Wong, B.; Lyle, E. A.; Williams, P. D.; Coburn, C. A.; Dorsey, B. D.; Barrow, J. C.; Stranieri, M. T.; Holahan, M. A.; Sitko, G. R.; Cook, J. J.; McMasters, D. R.; McDonough, C. M.; Sanders, W. M.; Wallace, A. A.; Clayton, F. C.; Bohn, D.; Leonard, Y. M.; Detwiler, T. J., Jr.; Lynch, J. J., Jr.; Yan, Y.; Chen, Z.; Kuo, L.; Gardell, S. J.; Shafer, J. A.; Vacca, J. P. Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines J. Med. Chem. 2003, 46, 461-473
199. Lee, Y. K.; Parks, D. J.; Lu, T.; Thieu, T. V.; Markotan, T.; Pan, W.; McComsey, D. F.; Milkiewicz, K. L.; Crysler, C. S.; Ninan, N.; Abad, M. C.; Giardino, E. C.; Maryanoff, B. E.; Damiano, B. P.; Player, M. R. 7-Fluoroindazoles as potent and selective inhibitors of factor Xa J. Med. Chem. 2008, 51, 282-297
200. Anilkumar, G. N.; Lesburg, C. A.; Selyutin, O.; Rosenblum, S. B.; Zeng, Q.; Jiang, Y.; Chan, T. Y.; Pu, H.; Vaccaro, H.; Wang, L.; Bennett, F.; Chen, K. X.; Duca, J.; Gavalas, S.; Huang, Y.; Pinto, P.; Sannigrahi, M.; Velazquez, F.; Venkatraman, S.; Vibulbhan, B.; Agrawal, S.; Butkiewicz, N.; Feld, B.; Ferrari, E.; He, Z.; Jiang, C. K.; Palermo, R. E.; McMonagle, P.; Huang, H. C.; Shih, N. Y.; Njoroge, G.; Kozlowski, J. A. I. Novel HCV NS5B polymerase inhibitors: discovery of indole 2-carboxylic acids with C3-heterocycles Bioorg. Med. Chem. Lett. 2011, 21, 5336-5341
201. Ohren, J. F.; Chen, H.; Pavlovsky, A.; Whitehead, C.; Zhang, E.; Kuffa, P.; Yan, C.; McConnell, P.; Spessard, C.; Banotai, C.; Mueller, W. T.; Delaney, A.; Omer, C.; Sebolt-Leopold, J.; Dudley, D. T.; Leung, I. K.; Flamme, C.; Warmus, J.; Kaufman, M.; Barrett, S.; Tecle, H.; Hasemann, C. A. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition Nat. Struct. Mol. Biol. 2004, 11, 1192-1197
202. Wallace, M. B.; Adams, M. E.; Kanouni, T.; Mol, C. D.; Dougan, D. R.; Feher, V. A.; O'Connell, S. M.; Shi, L.; Halkowycz, P.; Dong, Q. Structure-based design and synthesis of pyrrole derivatives as MEK inhibitors Bioorg. Med. Chem. Lett. 2010, 20, 4156-4158
203. Adams, M. E.; Wallace, M. B.; Kanouni, T.; Scorah, N.; O'Connell, S. M.; Miyake, H.; Shi, L.; Halkowycz, P.; Zhang, L.; Dong, Q. Design and synthesis of orally available MEK inhibitors with potent in vivo antitumor efficacy Bioorg. Med. Chem. Lett. 2012, 22, 2411-2414
204. Isshiki, Y.; Kohchi, Y.; Iikura, H.; Matsubara, Y.; Asoh, K.; Murata, T.; Kohchi, M.; Mizuguchi, E.; Tsujii, S.; Hattori, K.; Miura, T.; Yoshimura, Y.; Aida, S.; Miwa, M.; Saitoh, R.; Murao, N.; Okabe, H.; Belunis, C.; Janson, C.; Lukacs, C.; Schück, V.; Shimma, N. Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent Bioorg. Med. Chem. Lett. 2011, 21, 1795-1801
205. Razgulin, A. V.; Mecozzi, S. Binding properties of aromatic carbon-bound fluorine J. Med. Chem. 2006, 49, 7902-7906
206. Kim, D.; Wang, L.; Beconi, M.; Eiermann, G. J.; Fisher, M. H.; He, H.; Hickey, G. J.; Kowalchick, J. E.; Leiting, B.; Lyons, K.; Marsilio, F.; McCann, M. E.; Patel, R. A.; Petrov, A.; Scapin, G.; Patel, S. B.; Sinha Roy, R.; Wu, J. K.; Wyvratt, M. J.; Zhang, B. B.; Zhu, L.; Thornberry, N. A.; Weber, A. E. (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J. Med. Chem. 2005, 48, 141-151
207. Thornberry, N. A.; Weber, A. E. Discovery of JANUVIA (sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes Curr. Top. Med. Chem. 2007, 7, 557-568
208. Kim, D.; Kowalchick, J. E.; Brockunier, L. L.; Parmee, E. R.; Eiermann, G. J.; Fisher, M. H.; He, H.; Leiting, B.; Lyons, K.; Scapin, G.; Patel, S. B.; Petrov, A.; Pryor, K. D.; Sinha Roy, R.; Wu, J. K.; Zhang, X.; Wyvratt, M. J.; Zhang, B. B.; Zhu, L.; Thornberry, N. A.; Weber, A. E. Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from β-aminoamides bearing substituted triazolopiperidines J. Med. Chem. 2008, 51, 589-602
209. Xu, J.; Wei, L.; Mathvink, R. J.; Edmondson, S. D.; Eiermann, G. J.; He, H.; Leone, J. F.; Leiting, B.; Lyons, K. A.; Marsilio, F.; Patel, R. A.; Patel, S. B.; Petrov, A.; Scapin, G.; Wu, J. K.; Thornberry, N. A.; Weber, A. E. Discovery of potent, selective, and orally bioavailable oxadiazole-based dipeptidyl peptidase IV inhibitors Bioorg. Med. Chem. Lett. 2006, 16, 5373-5377
210. Edmondson, S. D.; Wei, L.; Xu, J.; Shang, J.; Xu, S.; Pang, J.; Chaudhary, A.; Dean, D. C.; He, H.; Leiting, B.; Lyons, K. A.; Patel, R. A.; Patel, S. B.; Scapin, G.; Wu, J. K.; Beconi, M. G.; Thornberry, N. A.; Weber, A. E. Fluoroolefins as amide bond mimics in dipeptidyl peptidase IV inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 2409-2413
211. Biftu, T.; Feng, D.; Qian, X.; Liang, G.-B.; Kieczykowski, G.; Eiermann, G.; He, H.; Leiting, B.; Lyons, K.; Petrov, A.; Sinha-Roy, R.; Zhang, B.; Scapin, G.; Patel, S.; Gao, Y.-D.; Singh, S.; Wu, J.; Zhang, X.; Thornberry, N. A.; Weber, A. E. (3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes Bioorg. Med. Chem. Lett. 2007, 17, 49-52
212. Liang, G.-B.; Qian, X.; Feng, D.; Biftu, T.; Eiermann, G.; He, H.; Leiting, B.; Lyons, K.; Petrov, A.; Sinha-Roy, R.; Zhang, B.; Wu, J.; Zhang, X.; Thornberry, N. A.; Weber, A. E. Optimization of 1,4-diazepan-2-one containing dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes Bioorg. Med. Chem. Lett. 2007, 17, 1903-1907
213. Liang, G.-B.; Qian, X.; Biftu, T.; Singh, S.; Gao, Y.-D.; Scapin, G.; Patel, S.; Leiting, B.; Patel, R.; Wu, J.; Zhang, X.; Thornberry, N. A.; Weber, A. E. Discovery of new binding elements in DPP-4 inhibition and their applications in novel DPP-4 inhibitor design Bioorg. Med. Chem. Lett. 2008, 18, 3706-3710
214. Biftu, T.; Scapin, G.; Singh, S.; Feng, D.; Becker, J. W.; Eiermann, G.; He, H.; Lyons, K.; Patel, S.; Petrov, A.; Sinha-Roy, R.; Zhang, B.; Wu, J.; Zhang, X.; Doss, G. A.; Thornberry, N. A.; Weber, A. E. Rational design of a novel, potent, and orally bioavailable DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin Bioorg. Med. Chem. Lett. 2007, 17, 3384-3387
215. Gao, Y.-D.; Feng, D.; Sheridan, R. P.; Scapin, G.; Patel, S. B.; Wu, J. K.; Zhang, X.; Sinha-Roy, R.; Thornberry, N. A.; Weber, A. E.; Biftu, T. Modeling assisted rational design of novel, potent, and selective pyrrolopyrimidine DPP-4 inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 3877-3879
216. Biftu, T.; Qian, X.; Chen, P.; Feng, D.; Scapin, G.; Gao, Y.-D.; Cox, J.; Sinha Roy, R.; Eiermann, G.; He, H.; Lyons, K.; Salituro, G.; Patel, S.; Petrov, A.; Xu, F.; Xu, S. S.; Zhang, B.; Caldwell, C.; Wu, J. K.; Lyons, K.; Weber, A. E. Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: profile of clinical candidate (2R,3S,5R)-2-(2,5-difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine (23) Bioorg. Med. Chem. Lett. 2013, 23, 5361-5366
217. Biftu, T.; Sinha-Roy, R.; Chen, P.; Qian, X.; Feng, D.; Kuethe, J. T.; Scapin, G.; Gao, Y. D.; Yan, Y.; Krueger, D.; Bak, A.; Eiermann, G.; He, J.; Cox, J.; Hicks, J.; Lyons, K.; He, H.; Salituro, G.; Tong, S.; Patel, S.; Doss, G.; Petrov, A.; Wu, J.; Xu, S. S.; Sewall, C.; Zhang, X.; Zhang, B.; Thornberry, N. A.; Weber, A. E. Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes J. Med. Chem. 2014, 57, 3205-3212
218. Kim, D.; Kowalchick, J. E.; Edmondson, S. D.; Mastracchio, A.; Xu, J.; Eiermann, G. J.; Leiting, B.; Wu, J. K.; Pryor, K. D.; Patel, R. A.; He, H.; Lyons, K. A.; Thornberry, N. A.; Weber, A. E. Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: close analogs of JANUVIA (sitagliptin phosphate) Bioorg. Med. Chem. Lett. 2007, 17, 3373-3377
219. Dubowchik, G. M.; Vrudhula, V. M.; Dasgupta, B.; Ditta, J.; Chen, T.; Sheriff, S.; Sipman, K.; Witmer, M.; Tredup, J.; Vyas, D. M.; Verdoorn, T. A.; Bollini, S.; Vinitsky, A. 2-Aryl-2,2-difluoroacetamide FKBP12 ligands: synthesis and X-ray structural studies Org. Lett. 2001, 3, 3987-3990
220. Harper, D. B.; O'Hagan, D. The fluorinated natural products Nat. Prod. Rep. 1994, 11, 123-133
221. Lauble, H.; Kennedy, M. C.; Emptage, M. H.; Beinert, H.; Stout, C. D. The reaction of fluorocitrate with aconitase and the crystal structure of the enzyme-inhibitor complex Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 13699-13703
222. Weeks, A. M.; Chang, M. C. Y. Catalytic control of enzymatic fluorine specificity Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 19667-19672
223. Weeks, A. M.; Keddie, N. S.; Wadoux, R. D. P.; O'Hagan, D.; Chang, M. C. Y. Molecular recognition of fluorine impacts substrate selectivity in the fluoroacetyl-CoA thioesterase FlK Biochemistry 2014, 53, 2053-2063
224. Fagerholm, U. The role of permeability in drug ADME/PK, interactions and toxicity, and the permeability-based classification system (PCS). Burger's Medicinal Chemistry and Drug Discovery, 7 th ed.; Abraham, D. J.; Rotella, D. P., Eds.; Wiley: New York, 2010; pp 367-380.
225. Lennernäs, H.; Abrahamsson, B. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension J. Pharm. Pharmacol. 2005, 57, 273-285
226. Smart, B. E. Fluorine substituent effects (on bioactivity) J. Fluorine Chem. 2001, 109, 3-11
227. Huchet, Q. A.; Kuhn, B.; Wagner, B.; Fischer, H.; Kansy, M.; Zimmerli, D.; Carreira, E. M.; Müller, K. On the polarity of partially fluorinated methyl groups J. Fluorine Chem. 2013, 152, 119-128
228. Pinto, D. J. P.; Orwat, M. J.; Wang, S.; Fevig, J. M.; Quan, M. L.; Amparo, E.; Cacciola, J.; Rossi, K. A.; Alexander, R. S.; Smallwood, A. M.; Luettgen, J. M.; Liang, L.; Aungst, B. J.; Wright, M. R.; Knabb, R. M.; Wong, P. C.; Wexler, R. R.; Lam, P. Y. S. Discovery of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa J. Med. Chem. 2001, 44, 566-578
229. Quan, M. L.; Lam, P. Y. S.; Han, Q.; Pinto, D. J. P.; He, M. Y.; Li, R.; Ellis, C. D.; Clark, C. G.; Teleha, C. A.; Sun, J. H.; Alexander, R. S.; Bai, S.; Luettgen, J. M.; Knabb, R. M.; Wong, P. C.; Wexler, R. R. Discovery of 1-(3′-aminobenzisoxazol-5′-yl)-3-trifluoromethyl-N-[2-fluoro-4-[(2′-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor J. Med. Chem. 2005, 48, 1729-1744
230. Chopra, D.; Row, T. N. G. Evaluation of the interchangeability of C-H and C-F groups: Insights from crystal packing in a series of isomeric fluorinated benzanilides CrystEngComm 2008, 10, 54-67
231. Nayak, S. K.; Kishore Reddy, M.; Row, T. N. G.; Chopra, D. Role of Hetero-halogen (F⋯X, X = Cl, Br, and I) or homo-halogen (X⋯X, X = F, Cl, Br, and I) interactions in substituted benzanilides Cryst. Growth Des. 2011, 11, 1578-1596
232. Kuhn, B.; Mohr, P.; Stahl, M. Intramolecular hydrogen bonding in medicinal chemistry J. Med. Chem. 2010, 53, 2601-2611
233. Weiss, M. M.; Williamson, T.; Babu-Khan, S.; Bartberger, M. D.; Brown, J.; Chen, K.; Cheng, Y.; Citron, M.; Croghan, M. D.; Dineen, T. A.; Esmay, J.; Graceffa, R. F.; Harried, S. S.; Hickman, D.; Hitchcock, S. A.; Horne, D. B.; Huang, H.; Imbeah-Ampiah, R.; Judd, T.; Kaller, M. R.; Kreiman, C. R.; La, D. S.; Li, V.; Lopez, P.; Louie, S.; Monenschein, H.; Nguyen, T. T.; Pennington, L. D.; Rattan, C.; San Miguel, T.; Sickmier, E. A.; Wahl, R. C.; Wen, P. H.; Wood, S.; Xue, Q.; Yang, B. H.; Patel, V. F.; Zhong, W. Design and preparation of a potent series of hydroxyethylamine containing β-secretase inhibitors that demonstrate robust reduction of central β-amyloid J. Med. Chem. 2012, 55, 9009-9024
234. Dineen, T. A.; Weiss, M. M.; Williamson, T.; Acton, P.; Babu-Khan, S.; Bartberger, M. D.; Brown, J.; Chen, K.; Cheng, Y.; Citron, M.; Croghan, M. D.; Dunn, R. T.; Esmay, J.; Graceffa, R. F.; Harried, S. S.; Hickman, D.; Hitchcock, S. A.; Horne, D. B.; Huang, H.; Imbeah-Ampiah, R.; Judd, T.; Kaller, M. R.; Kreiman, C. R.; La, D. S.; Li, V.; Lopez, P.; Louie, S.; Monenschein, H.; Nguyen, T. T.; Pennington, L. D.; San Miguel, T.; Sickmier, E. A.; Vargas, H. M.; Wahl, R. C.; Wen, P. H.; Whittington, D. A.; Wood, S.; Xue, Q.; Yang, B. H.; Patel, V. F.; Zhong, W. Design and synthesis of potent, orally efficacious hydroxyethylamine derived β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors J. Med. Chem. 2012, 55, 9025-9044
235. Kaller, M. R.; Harried, S. S.; Albrecht, B.; Amarante, P.; Babu-Khan, S.; Bartberger, M. D.; Brown, J.; Brown, R.; Chen, K.; Cheng, Y.; Citron, M.; Croghan, M. D.; Graceffa, R.; Hickman, D.; Judd, T.; Kriemen, C.; La, D.; Li, V.; Lopez, P.; Luo, Y.; Masse, C.; Monenschein, H.; Nguyen, T.; Pennington, L. D.; Miguel, T. S.; Sickmier, E. A.; Wahl, R. C.; Weiss, M. M.; Wen, P. H.; Williamson, T.; Wood, S.; Xue, M.; Yang, B.; Zhang, J.; Patel, V.; Zhong, W.; Hitchcock, S. A potent and orally efficacious, hydroxyethylamine-based inhibitor of β-secretase ACS Med. Chem. Lett. 2012, 3, 886-891
236. Hitchcock, S. A. Structural modifications that alter the P-glycoprotein efflux properties of compounds J. Med. Chem. 2012, 55, 4877-4895
237. Desai, P. V.; Raub, T. J.; Blanco, M. J. How hydrogen bonds impact P-glycoprotein transport and permeability Bioorg. Med. Chem. Lett. 2012, 22, 6540-6548
238. Kuduk, S. D.; Di Marco, C. N.; Chang, R. K.; Wood, M. R.; Schirripa, K. M.; Kim, J. J.; Wai, J. M. C.; DiPardo, R. M.; Murphy, K. L.; Ransom, R. W.; Harrell, C. M.; Reiss, D. R.; Holahan, M. A.; Cook, J.; Hess, J. F.; Sain, N.; Urban, M. O.; Tang, C.; Prueksaritanont, T.; Pettibone, D. J.; Bock, M. G. Development of orally bioavailable and CNS penetrant biphenylaminocyclopropane carboxamide bradykinin B1 receptor antagonists J. Med. Chem. 2007, 50, 272-282
239. Ettorre, A.; D'Andrea, P.; Mauro, S.; Porcelloni, M.; Rossi, C.; Altamura, M.; Catalioto, R. M.; Giuliani, S.; Maggi, C. A.; Fattori, D. HNK2 receptor antagonists. The use of intramolecular hydrogen bonding to increase solubility and membrane permeability Bioorg. Med. Chem. Lett. 2011, 21, 1807-1809
240. Swahn, B.-M.; Kolmodin, K.; Karlström, S.; von Berg, S.; Söderman, P.; Holenz, J.; Berg, S.; Lindström, J.; Sundström, M.; Turek, D.; Kihlström, J.; Slivo, C.; Andersson, L.; Pyring, D.; Rotticci, D.; Öhberg, L.; Kers, A.; Bogar, K.; von Kieseritzky, F.; Bergh, M.; Olsson, L.-L.; Janson, J.; Eketjäll, S.; Georgievska, B.; Jeppsson, F.; Fälting, J. Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides J. Med. Chem. 2012, 55, 9346-9361
241. Park, K. B.; Kitteringham, N. R. Effects of fluorine substitution on drug metabolism: pharmacological and toxicological implications Drug Metab. Rev. 1994, 26, 605-643
242. Tanaka, H.; Shishido, Y. Synthesis of aromatic compounds containing a 1,1-dialkyl-2-trifluoromethyl group, a bioisostere of the tert-alkyl moiety Bioorg. Med. Chem. Lett. 2007, 17, 6079-6085
243. Rowbottom, M. W.; Faraoni, R.; Chao, Q.; Campbell, B. T.; Lai, A. G.; Setti, E.; Ezawa, M.; Sprankle, K. G.; Abraham, S.; Tran, L.; Struss, B.; Gibney, M.; Armstrong, R. C.; Gunawardane, R. N.; Nepomuceno, R. R.; Valenta, I.; Hua, H.; Gardner, M. F.; Cramer, M. D.; Gitnick, D.; Insko, D. E.; Apuy, J. L.; Jones-Bolin, S.; Ghose, A. K.; Herbertz, T.; Ator, M. A.; Dorsey, B. D.; Ruggeri, B.; Williams, M.; Bhagwat, S.; James, J.; Holladay, M. W. Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1, 1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E J. Med. Chem. 2012, 55, 1082-1105
244. Barnes-Seeman, D.; Jain, M.; Bell, L.; Ferreira, S.; Cohen, S.; Chen, X. H.; Amin, J.; Snodgrass, B.; Hatsis, P. Metabolically stable tert-butyl replacement ACS Med. Chem. Lett. 2013, 4, 514-516
245. Westphal, M. W.; Wolfstädter, B. T.; Plancher, J.-M.; Gatfield, J.; Carreira, E. M. Evaluation of tert-butyl isosteres: case studies of physicochemical and pharmacokinetic properties, efficacies, and activities ChemMedChem 2015, 10, 461-469
246. Black, W. C.; Bayly, C. I.; Davis, D. E.; Desmarais, S.; Falgueyret, J. P.; Léger, S.; Chun, S. L.; Massé, F.; McKay, D. J.; Palmer, J. T.; Percival, M. D.; Robichaud, J.; Tsou, N.; Zamboni, R. Trifluoroethylamines as amide isosteres in inhibitors of cathepsin K Bioorg. Med. Chem. Lett. 2005, 15, 4741-4744
247. Isabel, E.; Mellon, C.; Boyd, M. J.; Chauret, N.; Descheînes, D.; Desmarais, S.; Falgueyret, J. P.; Gauthier, J. Y.; Khougaz, K.; Lau, C. K.; Léger, S.; Levorse, D. A.; Li, C. S.; Massé, F.; David Percival, M.; Roy, B.; Scheigetz, J.; Thérien, M.; Truong, V. L.; Wesolowski, G.; Young, R. N.; Zamboni, R.; Cameron Black, W. Difluoroethylamines as an amide isostere in inhibitors of cathepsin K Bioorg. Med. Chem. Lett. 2011, 21, 920-923
248. Miller, M. M.; Liu, Y.; Jiang, J.; Johnson, J. A.; Kamau, M.; Nirschl, D. S.; Wang, Y.; Harikrishnan, L.; Taylor, D. S.; Chen, A. Y. A.; Yin, X.; Seethala, R.; Peterson, T. L.; Zvyaga, T.; Zhang, J.; Huang, C. S.; Wexler, R. R.; Poss, M. A.; Lawrence, R. M.; Adam, L. P.; Salvati, M. E. Identification of a potent and metabolically stable series of fluorinated diphenylpyridylethanamine-based cholesteryl ester transfer protein inhibitors Bioorg. Med. Chem. Lett. 2012, 22, 6503-6508
249. Zhu, Y.; Olson, S. H.; Graham, D.; Patel, G.; Hermanowski-Vosatka, A.; Mundt, S.; Shah, K.; Springer, M.; Thieringer, R.; Wright, S.; Xiao, J.; Zokian, H.; Dragovic, J.; Balkovec, J. M. Phenylcyclobutyl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type I Bioorg. Med. Chem. Lett. 2008, 18, 3412-3416
250. Kerekes, A. D.; Esposite, S. J.; Doll, R. J.; Tagat, J. R.; Yu, T.; Xiao, Y.; Zhang, Y.; Prelusky, D. B.; Tevar, S.; Gray, K.; Terracina, G. A.; Lee, S.; Jones, J.; Liu, M.; Basso, A. D.; Smith, E. B. Aurora kinase inhibitors based on the imidazo[1,2-a]pyrazine core: fluorine and deuterium incorporation improve oral absorption and exposure J. Med. Chem. 2011, 54, 201-210
251. Xu, S.; Zhu, B.; Teffera, Y.; Pan, D. E.; Caldwell, C. G.; Doss, G.; Stearns, R. A.; Evans, D. C.; Beconi, M. G. Metabolic activation of fluoropyrrolidine dipeptidyl peptidase-IV inhibitors by rat liver microsomes Drug Metab. Dispos. 2005, 33, 121-130
252. Edmondson, S. D.; Mastracchio, A.; Mathvink, R. J.; He, J.; Harper, B.; Park, Y. J.; Beconi, M.; Di Salvo, J.; Eiermann, G. J.; He, H.; Leiting, B.; Leone, J. F.; Levorse, D. A.; Lyons, K.; Patel, R. A.; Patel, S. B.; Petrov, A.; Scapin, G.; Shang, J.; Roy, R. S.; Smith, A.; Wu, J. K.; Xu, S.; Zhu, B.; Thornberry, N. A.; Weber, A. E. (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective α-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J. Med. Chem. 2006, 49, 3614-3627
253. Sharma, R.; Sun, H.; Piotrowski, D. W.; Ryder, T. F.; Doran, S. D.; Dai, H.; Prakash, C. Metabolism, excretion, and pharmacokinetics of (3,3-difluoropyrrolidin-1- yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human Drug Metab. Dispos. 2012, 40, 2143-2161
254. Tremblay, M.; Bethell, R. C.; Cordingley, M. G.; Deroy, P.; Duan, J.; Duplessis, M.; Edwards, P. J.; Faucher, A. M.; Halmos, T.; James, C. A.; Kuhn, C.; Lacoste, J. E.; Lamorte, L.; Laplante, S. R.; Malenfant, é.; Minville, J.; Morency, L.; Morin, S.; Rajotte, D.; Salois, P.; Simoneau, B.; Tremblay, S.; Sturino, C. F. Identification of benzofurano[3,2-d]pyrimidin-2-ones, a new series of HIV-1 nucleotide-competing reverse transcriptase inhibitors Bioorg. Med. Chem. Lett. 2013, 23, 2775-2780
255. Irurre, J., Jr.; Casas, J.; Messeguer, A. Resistance to the 2,2,2-trifluoroethoxy aryl moiety to the cytochrome P-450 metabolism in rat liver microsomes Bioorg. Med. Chem. Lett. 1993, 3, 179-182
256. Williams, S. J.; Zammit, S. C.; Cox, A. J.; Shackleford, D. M.; Morizzi, J.; Zhang, Y.; Powell, A. K.; Gilbert, R. E.; Krum, H.; Kelly, D. J. 3′,4′-Bis-difluoromethoxycinnamoylanthranilate (FT061): an orally-active antifibrotic agent that reduces albuminuria in a rat model of progressive diabetic nephropathy Bioorg. Med. Chem. Lett. 2013, 23, 6868-6873
257. 14C-flecainide acetate in humans Drug Metab. Dispos. 1984, 12, 414-420
258. Harbeson, S. L.; Tung, R. D. Deuterium in drug discovery and development Annu. Rep. Med. Chem. 2011, 46, 403-417
259. Gant, T. G. Using deuterium in drug discovery: leaving the label in the drug J. Med. Chem. 2014, 57, 3595-3611
260. Kalgutkar, A. S.; Gardner, I.; Obach, R. S.; Shaffer, C. L.; Callegari, E.; Henne, K. R.; Mutlib, A. E.; Dalvie, D. K.; Lee, J. S.; Nakai, Y.; O'Donnell, J. P.; Boer, J.; Harriman, S. P. A comprehensive listing of bioactivation pathways of organic functional groups Curr. Drug Metab. 2005, 6, 161-225
261. Bertelsen, K. M.; Venkatakrishnan, K.; Von Moltke, L. L.; Obach, R. S.; Greenblatt, D. J. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine Drug Metab. Dispos. 2003, 31, 289-293
262. Rose, W. C.; Marathe, P. H.; Jang, G. R.; Monticello, T. M.; Balasubramanian, B. N.; Long, B.; Fairchild, C. R.; Wall, M. E.; Wani, M. C. Novel fluoro-substituted camptothecins: in vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization Cancer Chemother. Pharmacol. 2006, 58, 73-85
263. Van Goor, F.; Hadida, S.; Grootenhuis, P. D. J.; Burton, B.; Stack, J. H.; Straley, K. S.; Decker, C. J.; Miller, M.; McCartney, J.; Olson, E. R.; Wine, J. J.; Frizzell, R. A.; Ashlock, M.; Negulescu, P. A. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 18843-18848
264. Trachsel, D.; Hadorn, M.; Baumberger, F. Synthesis of fluoro analogues of 3,4-(methylenedioxy)amphetamine (MDA) and its derivatives Chem. Biodiversity 2006, 3, 326-336
265. Trachsel, D. Fluorine in psychedelic phenethylamines Drug Test. Anal. 2012, 4, 577-590
266. Miao, Z.; Zhu, L.; Dong, G.; Zhuang, C.; Wu, Y.; Wang, S.; Guo, Z.; Liu, Y.; Wu, S.; Zhu, S.; Fang, K.; Yao, J.; Li, J.; Sheng, C.; Zhang, W. A new strategy to improve the metabolic stability of lactone: discovery of (20S,21S)-21-fluorocamptothecins as novel, hydrolytically stable topoisomerase I inhibitors J. Med. Chem. 2013, 56, 7902-7910
267. Savoie, P. R.; Welch, J. T. Preparation and utility of organic pentafluorosulfanyl-containing compounds Chem. Rev. 2015, 115, 1130-1190
268. Craig, P. N. Interdependence between physical parameters and selection of substituent groups for correlation studies J. Med. Chem. 1971, 14, 680-684
269. Coteron, J. M.; Marco, M.; Esquivias, J.; Deng, X.; White, K. L.; White, J.; Koltun, M.; El Mazouni, F.; Kokkonda, S.; Katneni, K.; Bhamidipati, R.; Shackleford, D. M.; Angulo-Barturen, I.; Ferrer, S. B.; Jiménez-Díaz, M. B.; Gamo, F. J.; Goldsmith, E. J.; Charman, W. N.; Bathurst, I.; Floyd, D.; Matthews, D.; Burrows, J. N.; Rathod, P. K.; Charman, S. A.; Phillips, M. A. Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential J. Med. Chem. 2011, 54, 5540-5561
270. Deng, X.; Kokkonda, S.; El Mazouni, F.; White, J.; Burrows, J. N.; Kaminsky, W.; Charman, S. A.; Matthews, D.; Rathod, P. K.; Phillips, M. A. Fluorine modulates species selectivity in the triazolopyrimidine class of Plasmodium falciparum dihydroorotate dehydrogenase inhibitors J. Med. Chem. 2014, 57, 5381-5394
271. Altomonte, S.; Baillie, G. L.; Ross, R. A.; Riley, J.; Zanda, M. The pentafluorosulfanyl group in cannabinoid receptor ligands: synthesis and comparison with trifluoromethyl and tert-butyl analogues RSC Adv. 2014, 4, 20164-20176
272. Welch, J. T.; Lim, D. S. The synthesis and biological activity of pentafluorosulfanyl analogs of fluoxetine, fenfluramine, and norfenfluramine Bioorg. Med. Chem. 2007, 15, 6659-6666
273. Micheli, F.; Andreotti, D.; Braggio, S.; Checchia, A. A specific and direct comparison of the trifluoromethyl and pentafluorosulfanyl groups on the selective dopamine D3 antagonist 3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane template Bioorg. Med. Chem. Lett. 2010, 20, 4566-4568
274. Sun, L.; Bera, H.; Chui, W. K. Synthesis of pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors of thymidine phosphorylase Eur. J. Med. Chem. 2013, 65, 1-11
275. Sun, L.; Li, J.; Bera, H.; Dolzhenko, A. V.; Chiu, G. N. C.; Chui, W. K. Fragment-based approach to the design of 5-chlorouracil-linked-pyrazolo[1,5-a][1,3,5]triazines as thymidine phosphorylase inhibitors Eur. J. Med. Chem. 2013, 70, 400-410
276. Stump, B.; Eberle, C.; Schweizer, W. B.; Kaiser, M.; Brun, R.; Krauth-Siegel, R. L.; Lentz, D.; Diederich, F. Pentafluorosulfanyl as a novel building block for enzyme inhibitors: trypanothione reductase inhibition and antiprotozoal activities of diarylamines ChemBioChem 2009, 10, 79-83
277. Savoie, P. R.; Higashiya, S.; Lin, J. H.; Wagle, D. V.; Welch, J. T. Conformational impact of pentafluorosulfanylation on acyclic aliphatic molecules J. Fluorine Chem. 2012, 143, 281-286
278. Savoie, P. R.; Welch, J. M.; Higashiya, S.; Welch, J. T. Control of hydroxyl group conformation by the pentafluorosulfanyl group J. Fluorine Chem. 2013, 148, 1-5
279. Morgan, P.; Van Der Graaf, P. H.; Arrowsmith, J.; Feltner, D. E.; Drummond, K. S.; Wegner, C. D.; Street, S. D. A. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival Drug Discovery Today 2012, 17, 419-424
280. Mullard, A. Molecular imaging as a de-risking tool: coming into focus? Nat. Rev. Drug Discovery 2013, 12, 251-252
281. Matthews, P. M.; Rabiner, E. A.; Passchier, J.; Gunn, R. N. Positron emission tomography molecular imaging for drug development Br. J. Clin. Pharmacol. 2012, 73, 175-186
282. Cook, D.; Brown, D.; Alexander, R.; March, R.; Morgan, P.; Satterthwaite, G.; Pangalos, M. N. Lesssons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework Nat. Rev. Drug Discovery 2014, 13, 419-431
283. Kilbourn, M. R. Fluorine-18 Labeling of Radiopharmaceuticals; National Academy Press: Washington, DC, 1990.
284. Van de Bittner, G. C.; Ricq, E. L.; Hooker, J. M. A philosophy for CNS radiotracer design Acc. Chem. Res. 2014, 47, 3127-3134
285. Liang, T.; Neumann, C. N.; Ritter, T. Introduction of fluorine and fluorine-containing functional groups Angew. Chem., Int. Ed. 2013, 52, 8214-8264
286. 18F Labeling of arenes Angew. Chem., Int. Ed. 2012, 51, 11426-11437
287. Pretze, M.; Pietzsch, D.; Mamat, C. Recent trends in bioorthogonal click-radiolabeling reactions using fluorine-18 Molecules 2013, 18, 8618-8665
288. 18F-labeled radiotracers Curr. Org. Chem. 2013, 17, 2138-2152
289. Littich, R.; Scott, P. J. H. Novel strategies for fluorine-18 radiochemistry Angew. Chem., Int. Ed. 2012, 51, 1106-1109
290. 18F labeling of peptides and proteins J. Labelled Compd. Radiopharm. 2014, 57, 219-223
291. 18F]fluorination: new solutions to old problems Chem. Sci. 2014, 5, 4545-4553
292. Cole, E. L.; Stewart, M. N.; Littich, R.; Hoareau, R.; Scott, P. J. H. Radiosyntheses using fluorine-18: the art and science of late stage fluorination Curr. Top. Med. Chem. 2014, 14, 875-900
293. 18F]fluoride Nucl. Med. Mol. Imaging 2010, 44, 25-32
294. Li, Z.; Conti, P. S. Radiopharmaceutical chemistry for positron emission tomography Adv. Drug Delivery Rev. 2010, 62, 1031-1051
295. O'Hagan, D.; Deng, H. Enzymatic fluorination and biotechnological developments of the fluorinase Chem. Rev. 2015, 115, 634-649
296. 18F]fluoride using polymer cartridge Bull. Korean Chem. Soc. 2011, 32, 71-76
297. 18F-fluorination without azeotropic drying Nuklearmedizin 2012, 51, 1-8
298. Snyder, S. E.; Kilbourn, M. R. Chemistry of fluorine-18 radiopharmaceuticals. In Handbook of Radiopharmaceuticals: Radiochemistry and Applications; Welch, M. J.; Redvanly, C. S., Eds.; John Wiley & Sons Ltd.: New York, 2003; pp 195-227.
299. Bailey, D. L.; Townsend, D. W.; Valk, P. E.; Maisey, M. N., Eds. Positron Emission Tomography: Basic Sciences; Springer: New York, 2005.
300. De Goeij, J. J. M.; Bonardi, M. L. How do we define the concepts specific activity, radioactive concentration, carrier, carrier-free and no-carrier-added? J. Radioanal. Nucl. Chem. 2005, 263, 13-18
301. Bonardi, M. L.; Birattari, C.; Groppi, F.; Gini, L.; Mainardi, H. S. C. Cyclotron production and quality control of "high specific activity" radionuclides in "no-carrier-added" form for radioanalytical applications in the life sciences J. Radioanal. Nucl. Chem. 2004, 259, 415-419
302. 11C]carfentanil PET: replication in an independent cohort Int. J. Neuropsychopharmacol. 2014, 17, 2069-2074
303. 18F]fluoroethoxybenzovesamicol in rat and monkey brain: a radioligand for the vesicular acetylcholine transporter Nucl. Med. Biol. 2009, 36, 489-493
304. Orbay, H.; Hong, H.; Zhang, Y.; Cai, W. Positron emission tomography imaging of atherosclerosis Theranostics 2013, 3, 894-902
305. Bergman, J.; Solin, O. Fluorine-18-labeled fluorine gas for synthesis of tracer molecules Nucl. Med. Biol. 1997, 24, 677-683
306. Bergman, J.; Solin, O. Fluorine-18-labeled fluorine gas for synthesis of tracer molecules Nucl. Med. Biol. 1997, 24, 677-683
307. 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease J. Nucl. Med. 2013, 54, 1420-1427
308. Watson, D. A.; Su, M.; Teverovskiy, G.; Zhang, Y.; García-Fortanet, J.; Kinzel, T.; Buchwald, S. L. Formation of ArF from LPdAr(F): catalytic conversion of aryl triflates to aryl fluorides Science 2009, 325, 1661-1664
309. Noël, T.; Maimone, T. J.; Buchwald, S. L. Accelerating palladium-catalyzed C-F bond formation: use of a microflow packed-bed reactor Angew. Chem., Int. Ed. 2011, 50, 8900-8903
310. Lee, H. G.; Milner, P. J.; Buchwald, S. L. An improved catalyst system for the Pd-catalyzed fluorination of (hetero)aryl triflates Org. Lett. 2013, 15, 5602-5605
311. Tang, P.; Wang, W.; Ritter, T. Deoxyfluorination of phenols J. Am. Chem. Soc. 2011, 133, 11482-11484
312. Sladojevich, F.; Arlow, S. I.; Tang, P.; Ritter, T. Late-stage deoxyfluorination of alcohols with PhenoFluor J. Am. Chem. Soc. 2013, 135, 2470-2473
313. 18F]fluoroarenes from the radiofluorination of diaryl sulfoxides Chem. Commun. 2013, 49, 2151-2153
314. 2-mediated fluorination of aryltrifluoroborates with potassium fluoride J. Am. Chem. Soc. 2013, 135, 16292-16295
315. Fier, P. S.; Hartwig, J. F. Copper-mediated fluorination of aryl iodides J. Am. Chem. Soc. 2012, 134, 10795-10798
316. Ichiishi, N.; Canty, A. J.; Yates, B. F.; Sanford, M. S. Cu-catalyzed fluorination of diaryliodonium salts with KF Org. Lett. 2013, 15, 5134-5137
317. 18F]fluorination of (mesityl)(aryl)iodonium salts Org. Lett. 2014, 16, 3224-3227
318. Rotstein, B. H.; Stephenson, N. A.; Vasdev, N.; Liang, S. H. Spirocyclic hypervalent iodine(III)-mediated radiofluorination of non-activated and hindered aromatics Nat. Commun. 2014, 5, 4365 10.1038/ncomms5365
319. 18F fluorination of arenes Angew. Chem., Int. Ed. 2014, 53, 7751-7755
320. Welch, M. J.; Redvanly, C. S.; Eds. Handbook of Radiopharmaceuticals: Radiochemistry and Applications; John Wiley & Sons Ltd.: New York, 2003.
321. 18F-AV-45: a PET agent for Aβ plaques in the brain J. Nucl. Med. 2009, 50, 1887-1894
322. Zhang, W.; Oya, S.; Kung, M. P.; Hou, C.; Maier, D. L.; Kung, H. F. F-18 stilbenes as PET imaging agents for detecting β-amyloid plaques in the brain J. Med. Chem. 2005, 48, 5980-5988
323. 18F-AV-45 (flobetapir F 18) J. Nucl. Med. 2010, 51, 913-920
324. Clark, C. M.; Schneider, J. A.; Bedell, B. J.; Beach, T. C.; Bilker, W. B.; Mintun, M. A.; Pontecorvo, M. J.; Hefti, F.; Carpenter, A. P.; Flitter, M. L.; Krautkramer, M. J.; Kung, H. F.; Coleman, R. E.; Doraiswamy, P. M.; Fleisher, A. S.; Sabbagh, M. N.; Sadowsky, C. H.; Reiman, P. E. M.; Zehntner, S. P.; Skovronsky, D. M. Use of florbetapir-PET for imaging β-amyloid pathology JAMA, J. Am. Med. Assoc. 2011, 305, 275-283
325. 18F]AV-45) for positron emission tomography amyloid imaging J. Labelled Compd. Radiopharm. 2013, 56, 295-300
326. 18F]fluorinated fatty acid analogs Nucl. Med. Biol. 2011, 38, 435-441
327. 18F]fluoride Nucl. Med. Mol. Imaging 2010, 44, 25-32
328. N2 reactions catalyzed by protic solvents: facile fluorination for isotopic labeling of diagnostic molecules J. Am. Chem. Soc. 2006, 128, 16394-16397
329. Zhang, W.; Curran, D. P. Synthetic applications of fluorous solid-phase extraction (F-SPE) Tetrahedron 2006, 62, 11837-11865
330. 18F]fluoride ion: nucleophilic fluorination as the detagging process Angew. Chem., Int. Ed. 2009, 48, 586-589
331. 18F]fluorohydrins J. Am. Chem. Soc. 2014, 136, 5291-5294
332. Yang, D. J.; Wallace, S.; Cherif, A.; Li, C.; Gretzer, M. B.; Kim, E. E.; Podoloff, D. A. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia Radiology 1995, 194, 795-800
333. Kurihara, H.; Honda, N.; Kono, Y.; Arai, Y. Radiolabelled agents for PET imaging of tumor hypoxia Curr. Med. Chem. 2012, 19, 3282-3289
334. 18F]fluoride for PET imaging J. Am. Chem. Soc. 2014, 136, 6842-6845
335. 18F]trifluoromethyl groups Chem. Commun. 2011, 47, 11873-11875
336. Fawaz, M. V.; Brooks, A. F.; Rodnick, M. E.; Carpenter, G. M.; Shao, X.; Desmond, T. J.; Sherman, P.; Quesada, C. A.; Hockley, B. G.; Kilbourn, M. R.; Albin, R. L.; Frey, K. A.; Scott, P. J. H. High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer's disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection ACS Chem. Neurosci. 2014, 5, 718-730
337. 18F]trifluoromethylation of aryl and heteroaryl iodides for PET imaging Nat. Chem. 2013, 5, 941-944
338. 18F-labeled trifluoromethyl arenes Chem. Commun. 2014, 50, 6056-6059
339. Nyffeler, P. T.; Durón, S. G.; Burkart, M. D.; Vincent, S. P.; Wong, C.-H. Selectfluor: mechanistic insight and applications Angew. Chem., Int. Ed. 2005, 44, 192-212
340. 18F]selectfluor bis(triflate) Angew. Chem., Int. Ed. 2010, 49, 6821-6824
341. 18F]fluoro-L-DOPA Chem. Commun. 2013, 49, 1386-1388
342. Kumakura, Y.; Cumming, P. PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches Neuroscientist 2009, 15, 635-650
343. 18F-DOPA PET and PET/CT Nucl. Med. Commun. 2012, 33, 563-570
344. Lee, E.; Kamlet, A. S.; Powers, D. C.; Neumann, C. N.; Boursalian, G. B.; Furuya, T.; Choi, D. C.; Hooker, J. M.; Ritter, T. A fluoride-derived electrophilic late-stage fluorination reagent for PET imaging Science 2011, 334, 639-642
345. 18F] fluoride J. Am. Chem. Soc. 2012, 134, 17456-17458
346. Campbell, M. G.; Ritter, T. Late-stage fluorination: from fundamentals to application Org. Process Res. Dev. 2014, 18, 474-480
347. 18F-fluorination to PET radiotracer development: overcoming hurdles to translation PLoS One 2013, 8, e59187
348. 18F]MDL100907 enabled by Ni-mediated fluorination ACS Chem. Neurosci. 2014, 5, 611-615
349. Prescher, J. A.; Bertozzi, C. R. Chemistry in living systems Nat. Chem. Biol. 2005, 1, 13-21
350. Sletten, E. M.; Bertozzi, C. R. Bioorthogonal chemistry: fishing for selectivity in a sea of functionality Angew. Chem., Int. Ed. 2009, 48, 6974-6998
351. 18F for positron emission tomography Curr. Top. Med. Chem. 2010, 10, 1669-1679
352. 18F-labeled proteins Curr. Pharm. Biotechnol. 2010, 11, 572-580
353. 18F-Radionuclide chemistry Mol. Med. Med. Chem. 2012, 6, 335-382
354. Blackman, M. L.; Royzen, M.; Fox, J. M. Tetrazine ligation: fast bioconjugation based on inverse-electron-demand Diels-Alder reactivity J. Am. Chem. Soc. 2008, 130, 13518-13519
355. Wild, D.; Wicki, A.; Mansi, R.; Behe, M.; Keil, B.; Bernhardt, P.; Christofori, G.; Ell, P. J.; Macke, H. R. Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT J. Nucl. Med. 2010, 51, 1059-1067
356. 18F-Radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma Eur. J. Nucl. Med. Mol. Imaging 2012, 39, 463-473
357. 18F-Radiolabeled GLP-1 analog exendin-4 for PET/CT imaging of insulinoma in small animals Nucl. Med. Commun. 2013, 34, 701-708
358. 64Cu Labeled sarcophagine exendin-4 for microPET imaging of glucagon like peptide-1 receptor expression Theranostics 2014, 4, 770-777
359. 18F-labeled tetrazine with favorable pharmacokinetics for bioorthogonal PET imaging Angew. Chem., Int. Ed. 2014, 53, 9655-9659
360. 18F-labelled norbornene derivative for copper-free click chemistry reactions Org. Biomol. Chem. 2013, 11, 3817-3825
361. 18F]fluorobenzoate using a Siemens/CTI chemistry process control unit (CPCU) Appl. Radiat. Isot. 2007, 65, 199-203
362. 18F]fluorobenzoate on an IBA Synthera module J. Labelled Compd. Radiopharm. 2011, 54, 671-673
363. Gonzalez, N.; Moody, T. W.; Igarashi, H.; Ito, T.; Jensen, R. T. Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states Curr. Opin. Endocrinol., Diabetes Obes. 2008, 15, 58-64
364. 18F-radiolabelling Org. Biomol. Chem. 2011, 9, 136-140
365. 18F-Labeled fluorodeoxyglucose for PET imaging: the working mechanism and its clinical implication Drugs Future 2001, 26, 659-668
366. 18F]FDG) Bioorg. Med. Chem. Lett. 2009, 19, 5426-5428
367. 18F]FDG Bioconjugate Chem. 2009, 20, 432-436
368. 18F-Fluoroglucosylation of peptides, exemplified on cyclo(RGDfK) Eur. J. Nucl. Med. Mol. Imaging 2009, 36, 1469-1474
369. 18F]-labeled aryltrifluoroborate radiotracers: in vivo positron emission tomography imaging of stable aryltrifluoroborate clearance in mice J. Am. Chem. Soc. 2008, 130, 12045-12055
370. 18F]marimastat-aryltrifluoroborate as a probe for in vivo positron emission tomography imaging in cancer Cancer Res. 2010, 70, 7562-7569
371. 18F-labeling of an aryltrifluoroborate bioconjugate by isotope exchange at very high specific activity J. Labelled Compd. Radiopharm. 2012, 55, 491-496
372. 18F radiolabeling for PET J. Nucl. Med. 2009, 50, 991-998
373. 6-specific peptide Nucl. Med. Biol. 2014, 41, 43-50
374. 19F-arytrifluroborate in high yield and at extraordinarily high specific activity with preliminary in vivo tumor imaging Nucl. Med. Biol. 2013, 40, 841-849